BUENOS AIRES, Argentina, September 16, 2021 – Today, Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (‘Takeda’) announced that it has entered into an agreement to dispose of a selection of non-core products from the Company’s portfolio sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama and other countries of Central America and the Caribbean that make up the Southern Cone, the Andean region, Mexico and the regions of Central America and the Caribbean (SAM) in its Growth and Emerging Markets business unit (GEM BU) in Adium Pharma SA (‘Adium’), subject to customary legal and regulatory closing conditions.
The divestiture portfolio includes five non-essential products, mainly prescription gastroenterology assets:
Pantoprazole, Alevian, Dexlansoprazole, Riopan, Faktu. The transaction is expected to be finalized in the second half of 2021, subject to the satisfaction of customary closing conditions. Until then, Takeda retains ownership of these products and is responsible for ensuring patient access to them.
“We are confident that Adium is well positioned to ensure continued patient access to the products that are the subject of this transaction,” said Ricardo Marek, President of the Business Unit (BU) Growth & Emerging Markets (GEM) by Takeda. âThe strategy adopted by our GEM BU helps accelerate patients’ sustainable access to innovation. Through this divestment, we will have a greater ability to focus on strengthening our efforts in key therapeutic areas to meet the needs of patients living with severe or rare disease. Additionally, it helps Takeda achieve its ambition to become a global, value-driven, R&D-driven biopharmaceutical leader. ‘
Adium, a pharmaceutical company founded in 1975 with headquarters in Uruguay, operates in 18 Latin American countries, is dedicated to the development, production and marketing of pharmaceuticals, providing access to doctors and patients in America Latin America, to innovative and quality treatments with a commercial portfolio that includes exclusive brand generics and innovative licensed pharmaceuticals in the fields of oncology, rheumatology, pain, urology, women’s health, neurology, cardiology and gastroenterology.
âThe divestiture reinforces Takeda’s commitment to deliver highly innovative products with a greater focus on our five strategic business areas as part of our global long-term growth strategy,â said Gabriela Pittis, President of SAM domain for Takeda’s GEM BU. âUnder this agreement, Takeda will continue to develop and supply the products covered by this contract for the next five years to Adium, in line with the company’s goal of delivering better health to people and a better future for the people. world. ”
Takeda has reached an agreement to divest its portfolio of five pharmaceutical products, primarily prescription assets sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica and Panama, as well as other countries in the world. Central America and the Caribbean in Adium, subject to customary legal and regulatory closing conditions.
Under this agreement, Takeda remains responsible for the development and delivery of these products to Adium over the next five years, which will allow patients to have continued access to these drugs.
Takeda is being advised by Deloitte as our financial advisor and Marval O’Farrell & Mairal as our legal advisor in this transaction.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided through our commitment to patients, our staff and the planet. Takeda focuses its R&D efforts in four therapeutic areas: oncology, rare genetics and hematology, neuroscience and gastroenterology (GI). We also make targeted investments in R&D in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a pipeline. robust and diverse. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
Takeda GEM BU
+54 9 11 5586 6768
Communication JM Oribe
JosÃ© Maria Oribe
+ 54 9 11 5412-0205
Contact for investors:
+ 81- (0) 3-3278-2306
For the purposes of this notice, âpress releaseâ means this document, any oral presentation, any question-and-answer session, and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (âTakedaâ) in connection with this release. This press release (including any oral briefing and any related question and answer) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of an offer to ‘buy, acquire, subscribe, exchange, sell or otherwise dispose of securities or seek a vote or approval in any jurisdiction. No shares or other securities are offered to the public through this press release. No offering of securities will be made in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. This press release is given (along with any other information that may be provided to the recipient) on the condition that it is intended to be used by the recipient for informational purposes only (and not for the evaluation of a investment, acquisition, disposal or any other transaction). Any breach of these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda has direct and indirect investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “our” and “our” are also used to designate subsidiaries in general or those who work for them. These expressions are also used when it is not useful to identify the particular company or companies.
This press release and any material distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, goals and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “belief”, “hopes”, “continues”, “expects”, “objectives”, “intentions”, “ensures” , ‘Will’, ‘may’, ‘should’, ‘would’, ‘might’ ‘anticipate’, ‘estimate’, ‘projects’ or similar expressions or their negative. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: economic circumstances surrounding the global operations of Takeda, including general economic conditions in Japan and the United States; competitive pressures and developments; changes in applicable laws and regulations, including global healthcare reforms; the challenges inherent in the development of new products, including the uncertainty of clinical success and the decisions of regulatory authorities and their timing; the uncertainty of the commercial success of new and existing products; manufacturing difficulties or delays; fluctuations in interest rates and exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in the countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to dispose of assets that are not essential to Takeda’s operations and the timing of such disposal (s); and other factors identified in Takeda’s most recent annual report on Form 20-F and Takeda’s other reports filed with the United States Securities and Exchange Commission, available on Takeda’s website at address: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock market rules. Past performance is not an indicator of future results and Takeda’s results or statements in this press release may not be indicative, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information on products which may not be available in all countries, or which may be available under different brands, for different indications, at different strengths or at different strengths. Nothing in this material should be construed as a solicitation, promotion or advertisement for any prescription drugs, including those in development.